Wall Street analysts expect that Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) will post $4.55 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Intellipharmaceutics International’s earnings, with estimates ranging from $3.50 million to $5.60 million. Intellipharmaceutics International reported sales of $560,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 712.5%. The business is scheduled to issue its next earnings results on Thursday, October 12th.

On average, analysts expect that Intellipharmaceutics International will report full-year sales of $4.55 million for the current year, with estimates ranging from $11.74 million to $14.60 million. For the next financial year, analysts expect that the business will post sales of $26.10 million per share, with estimates ranging from $19.90 million to $32.30 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Intellipharmaceutics International.

Several equities analysts have weighed in on the company. Maxim Group restated a “buy” rating and set a $6.00 price objective on shares of Intellipharmaceutics International in a research note on Friday, June 30th. ValuEngine upgraded Intellipharmaceutics International from a “sell” rating to a “hold” rating in a research note on Friday, May 26th. Finally, Zacks Investment Research cut Intellipharmaceutics International from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $3.63.

COPYRIGHT VIOLATION WARNING: “Intellipharmaceutics International Inc. (IPCI) Expected to Announce Quarterly Sales of $4.55 Million” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/06/intellipharmaceutics-international-inc-ipci-expected-to-announce-quarterly-sales-of-4-55-million.html.

Shares of Intellipharmaceutics International (IPCI) traded down 4.1134% on Friday, reaching $0.9301. 121,940 shares of the company were exchanged. Intellipharmaceutics International has a 12 month low of $0.81 and a 12 month high of $3.35. The company’s market cap is $28.44 million. The company’s 50-day moving average price is $1.31 and its 200 day moving average price is $2.01.

A number of large investors have recently modified their holdings of IPCI. Advisor Group Inc. lifted its stake in Intellipharmaceutics International by 57.7% during the 2nd quarter. Advisor Group Inc. now owns 47,409 shares of the company’s stock valued at $100,000 after acquiring an additional 17,342 shares in the last quarter. Argent Trust Co raised its stake in shares of Intellipharmaceutics International by 52.5% during the 2nd quarter. Argent Trust Co now owns 59,693 shares of the company’s stock worth $125,000 after purchasing an additional 20,556 shares during the period. Finally, First Foundation Advisors raised its stake in shares of Intellipharmaceutics International by 172.1% during the 1st quarter. First Foundation Advisors now owns 274,592 shares of the company’s stock worth $686,000 after purchasing an additional 173,692 shares during the period. Institutional investors and hedge funds own 4.24% of the company’s stock.

Intellipharmaceutics International Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Get a free copy of the Zacks research report on Intellipharmaceutics International (IPCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related stocks with our FREE daily email newsletter.